RCC Laboratories India Private Limited Revenue and Competitors

Location

N/A

Total Funding

Consumer

Industry

Estimated Revenue & Valuation

  • RCC Laboratories India Private Limited's estimated annual revenue is currently $10.2M per year.(i)
  • RCC Laboratories India Private Limited's estimated revenue per employee is $125,500

Employee Data

  • RCC Laboratories India Private Limited has 81 Employees.(i)
  • RCC Laboratories India Private Limited grew their employee count by 7% last year.

RCC Laboratories India Private Limited's People

NameTitleEmail/Phone
1
PathologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$180.5M1006-3%$109.1MN/A
#2
$31.2M231-2%$122.3MN/A
#3
$256.6M14307%$28MN/A
#4
$574.3M32009%$358.2MN/A
#5
$12.9M1032%$9.4MN/A
#6
$40.2M29833%$16MN/A
#7
$101.7M6383%$33.2MN/A
#8
$13.6M108-9%$8MN/A
#9
$6.4M5712%N/AN/A
#10
$3.7M390%$2.4MN/A
Add Company

What Is RCC Laboratories India Private Limited?

- RCC Laboratories India Private Limited is one of the leading contract research organizations providing preclinical and safety Toxicology & chemical testing globally. - We maintain high quality standards and services and remain a leader in Contract Research Services internationally. - RCC complies with the OECD principles of Good Laboratory Practice (GLP) and is Certified by GLP monitoring authority of the Government of India (NGCMA) - All studies are conducted at RCC in accordance with the regulatory requirements of the OECD, Schedule Y, EU, EPA, ICH, OPPTS, ISO etc.

keywords:N/A

N/A

Total Funding

81

Number of Employees

$10.2M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RCC Laboratories India Private Limited News

2022-03-22 - Form 10-K Werewolf Therapeutics, For: Dec 31

Whereas many cancer treatments were historically limited to surgical ... Aldesleukin is approved for the treatment of metastatic RCC and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A81305%N/A
#2
$5.9M81-6%N/A
#3
$10.1M819%N/A
#4
$5.9M8111%N/A
#5
$5.9M828%N/A